Figure 2.

Efficacy of mRNA vaccines in the mouse model. (A) Timeline of experimental design in the mice. (B) Normalized body weight of immunized mice (n = 15 for each group). Red arrows indicate vaccination (first dose) and booster (second dose). (C) Neutralizing antibody titers against BVDV-1 determined at days 0, 35, 42, 49, and 56 based on immunofluorescence inhibition (n = 3, each for sera sample combined from 5 mice). (D) Effects of vaccination on leukocytes (WBC), lymphocytes (LYM), intermediate cells (IMD), and granulocytes (GRA) on day 56 (n = 15 presented as black dots for each group). N.S. indicates that there was no significant difference between the capped and capless vaccine, * p < 0.05, ** p < 0.01.